21 results about "Allergy prevention" patented technology

The invention, which relates to the technical field of medical data processing, discloses a nasal allergy prevention and management system comprising a data acquisition module, a data analysis module, an allergy prediction module and a terminal management module. The data acquisition module is used for acquiring a personal data set, a nose ultrasonic Doppler image and a nose near-infrared image of a tester; the data analysis module is used for performing quantitative coding processing on the personal data set of the testee, and performing feature extraction on the nose ultrasonic Doppler image and the nose near-infrared image through a first convolutional neural network path and a second convolutional neural network path respectively; the allergy prediction module is used for performing three-phase feature fusion on the personal data feature vector, the ultrasonic Doppler output feature map and the near-infrared output feature map to obtain output fusion features, and performing prediction classification on the output fusion features to obtain a nose allergy prevention result; and the terminal management module is used for providing a display interface for a user, receiving a user operation instruction, establishing a personal file of a tester and storing data.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The present invention relates to treatment and prevention of allergic diseases and, specifically, to an allergic disease immunomodulation method, which suppresses SIRT7 of nasal cavity epithelial cells to inhibit allergy mediators. The present invention suppresses SIRT7 of nasal cavity epithelial cells to inhibit the secretion of epithelial cell cytokines (TSLP), which recognize allergens to attract immune cells that induce an immune response, so that high-level processes of allergic reactions are blocked, and thus allergic diseases can be fundamentally treated and prevented.

The present invention relates to a composition comprising the supernatant of a supernatant of a blood mononuclear cell (PBMC) cell culture for use in the treatment / or prevention of allergies or allergic reactions caused by the administration of at least one food and / or inhaled allergen or the systemic administration of at least one drug to the body of a human or mammal.

The invention discloses a method for constructing a Yunnan pine pollen allergy animal model, which belongs to the technical field of Yunnan pine pollen allergy prevention and treatment and comprises the following steps: preparing Yunnan pine pollen allergens and sensitizing non-human mammals. The sensitization treatment comprises a basic sensitization treatment stage and an excitation sensitization treatment stage: in the basic sensitization treatment stage, peritoneal sensitization is carried out once a week and is continued for four weeks; in the nasal-drop sensitization treatment stage, different test substances with the concentration 2 times that of the basic sensitization stage are used for continuous 7-day quantitative nasal-drop excitation, and the nasal drop dosage is 2 microliters / g, and the symptoms of the mouse are observed within 10 minutes after nasal-drop excitation is completed each time. The allergic animal model constructed by adopting the crude extract of the pinus yunnanensis pollen allergen is the first animal model research related to pinus yunnanensis allergy at present, and a reference basis can be provided for subsequent experimental research on the aspect of deep research on pinus yunnanensis pollen allergy; a research model is provided for clinical research on the Yunnan pine pollen allergy or screening of medicines for resisting the Yunnan pine pollen allergy.

The present application addresses the problem of providing a regulatory T cell induction promoter containing D-sorbose and / or D-allose as an active ingredient. The problem is solved by providing a regulatory T cell induction promoter containing D-sorbose and / or D-allose as an active ingredient.

The invention relates to a nutritional composition comprising the synergistic combination of a postbiotic mixture comprising inactivated L. rhamnosus LGG and butyric acid or butyrate, a Perilla frutescens dry extract and quercetin, as well as its use in the therapeutic or preventive treatment of allergic disease or condition.

To provide a composition for use in the treatment or prevention of an allergic disorder.SOLUTION: The present invention provides compounds having the formulae or combinations thereof, where R1, R2, R3, R4, R5, and R6 independently represent a long chain fatty acid with between 16 and 20 carbons.SELECTED DRAWING: Figure 3

The present application relates to the field of cosmetic technology, and more particularly to a kind of acne, anti-allergic skin care product composition and preparation method thereof.The present application uses emollient, humectant, emulsifier, thickening agent, bamboo leaf pricklyash extract, saffron extract, purple magnolia extract, gentian extract, salicylic acid and water to prepare skin care product, and the skin care product has excellent acne and anti-allergic properties;After 7 days of using the skin care product of the present application, the improvement rate of skin acne lesion red area reaches 20.34%, and the improvement rate of acne quantity reaches 40.66%.

The aim is to provide technology that helps prevent allergic reactions by appropriately disclosing information about school lunches to parents. [Solution] A school lunch information management system comprising a school lunch information management device and a parent terminal device, wherein the school lunch information management device comprises a menu acquisition unit that acquires menu allergen information relating to the menu of a general meal, which is a school lunch provided to a typical student, and the allergens included in the general meal menu; a student information acquisition unit that acquires student information relating a student and the student's allergens; and a display information generation unit that generates display information to notify the parent terminal device of the type of school lunch provided to the student, wherein the parent terminal device comprises a parent-side output unit that outputs a student menu screen including the type, and the type includes at least a distinction between a general meal and a packed lunch.

The invention relates to a tolerogenic polypeptide capable of binding to an MHC Class II molecule independent of antigen processing, which is derived from Der p 1, and its uses in the treatment or prevention of an allergy. The invention also relates to method of treating or preventing an allergy in a subject in need thereof, comprising administering to the subject a therapeutically affective amount of the tolerogenic polypeptide.

The multi-modal biofeedback allergy defense massage control method comprises the following steps: acquiring multi-modal data of a user in a massage process in real time, determining whether the user has an allergy symptom before massage, and when the user has the allergy symptom before massage, outputting the acquired multi-modal data at a first moment as first multi-modal data; when the user does not have allergy symptoms before massage, constructing an antagonistic allergy risk model based on sympathetic / parasympathetic nerve activity indexes; performing real-time risk assessment by the antagonistic allergy risk model based on the multi-modal data acquired in real time, and outputting the multi-modal data as second multi-modal data when the risk assessment result is that the user has an allergy symptom; constructing a massage control model, and adjusting massage parameters of the massage equipment based on the first multi-modal data or the second multi-modal data by adopting the massage control model; according to the invention, the massage parameters of the user who is allergic or allergic in the massage process can be adjusted, so that the allergy symptom is relieved.

The invention relates to the technical field of infant nursing materials, in particular to a peritoneal belly for preventing allergy of an infant navel patch adhesive. Comprising a belly body, the belly body is made of 65% pure cotton and 35% modal blended materials, and an inner side layer is made of tencel fiber skin-care fabric containing 3%-5% of mint extract; a ring structure is arranged on the belly body, and the edge of the belly body is formed by adopting an ultrasonic hot cutting technology and is subjected to edge covering treatment for placing medicinal materials; a square pocket with a covering ring structure is sewn on one side of the belly body, the edge of the pocket adopts a three-thread overlock seamless sewing process, and a sewing thread is a corn fiber sewing thread; the diameter of a circular ring of the ring structure is 1-3 cm. The invention provides the bib which effectively reduces the allergy risk, is stable and fixed, is not easy to fall off, is breathable and comfortable, reduces the skin irritation, is multifunctional, improves the use experience, is safe and environment-friendly, and is suitable for infants.

The invention discloses an anti-allergic inflammation composition and a preparation method and application thereof, the active ingredients of the composition comprise sphingomyelin and beta-arbutin, and the concentration ratio of the sphingomyelin to the beta-arbutin is 1: 2-2: 1. The sphingomyelin and beta-arbutin composite formula has a huge application prospect in the development of anti-allergic inflammation products (such as respiratory mucosa protective agents, skin anti-inflammatory care products, allergy prevention dietary supplements and the like).

The invention discloses a fresh and fine private care antibacterial nursing spray and a preparation method thereof, and relates to the technical field of daily nursing materials. The fresh and fine private care bacteriostatic nursing spray is prepared from the following components in parts by mass: 50 to 90 parts of pure water, 0.5 to 15 parts of a traditional Chinese medicine bacteriostatic agent, 0.1 to 2 parts of a chemical bacteriostatic agent, 0.1 to 2 parts of an antipruritic agent, 0.5 to 25 parts of a soothing humectant, 0.1 to 3 parts of an aromatic freshener, 0.01 to 0.5 part of a stabilizer, 0.01 to 0.4 part of a preservative, 0.01 to 1 part of a surfactant and 0.01 to 0.5 part of a pH regulator, the invention relates to a preparation method of a fresh and fine private care antibacterial nursing spray. The spray is used in a spraying manner, the use process is more convenient, the spray has multiple effects of resisting bacteria, diminishing inflammation, resisting oxidation, resisting allergy, preventing infection, enhancing immunity and the like, the effects of nourishing skin, eliminating peculiar smell, relieving pruritus, preventing allergy and inhibiting bacterial growth can be achieved, and comfortable, fine, fresh and pleasant experience is brought to consumers.

The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and / or prophylaxis of allergy and associated allergic diseases and also of cancer.

The present invention provides an activator of CD4+Foxp3+ regulatory T cells for use in treating or preventing an allergy to Aspergillus or a lung disease or lung condition associated with an allergy to Aspergillus or associated with a pathogen-driven immune response in a subject, wherein the activator of CD4+Foxp3+ regulatory T cells binds to domain 2 of CD4.

The invention pertains to interleukin-1 (IL-1) and compositions comprising the same for use in the prevention and / or the treatment of an allergy, particularly in a method of desensitization. The invention also pertains to compositions comprising IL-1 with an allergen, medical devices comprising the same and kits for desensitization.

The present invention relates to a composition comprising the supernatant of a cell culture of peripheral blood mononuclear cells (PBMCs) for use in the treatment or prevention of an allergy or allergic reaction caused by the administration of at least one food to the human body or a mammal and / or the inhalation of an allergen or the systemic administration of at least one drug.

The present invention relates to a composition comprising a Bifidobacterium longum transition type microorganism and a mixture of human milk oligosaccharides (HMO) consisting of 2 '-fucosyllactose (2'-FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6 '-sialic acid lactose (6SL) and 3'-sialic acid lactose (3SL) and 3-fucosyllactose (3-FL) and / or lactose-N-neotetraose (LNnT). The invention also relates to the use of the composition for preventing, reducing the risk of, and / or treating an infection in an individual. The present invention also provides compositions for promoting long term immune benefit in an individual, preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing a respiratory condition in an individual and / or preventing and / or reducing the risk of developing asthma in an individual.